| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DXCM | Common Stock | Award | $5.30 | +5.3K | +42.28% | $0.00* | 17.8K | Mar 8, 2022 | Direct | F1, F2 |
| transaction | DXCM | Common Stock | Disposed to Issuer | -$78K | -192 | -1.08% | $406.06 | 17.6K | Mar 9, 2022 | Direct | F2, F3 |
| transaction | DXCM | Common Stock | Disposed to Issuer | -$175K | -432 | -2.45% | $406.06 | 17.2K | Mar 9, 2022 | Direct | F2, F3 |
| transaction | DXCM | Common Stock | Disposed to Issuer | -$90.6K | -223 | -1.3% | $406.06 | 17K | Mar 9, 2022 | Direct | F2, F3 |
| transaction | DXCM | Common Stock | Disposed to Issuer | -$395K | -974 | -5.74% | $406.06 | 16K | Mar 9, 2022 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. |
| F2 | Included in this number are 13,675 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |
| F3 | Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |